SeaStar Medical Holding Business Summary

SeaStar Medical Holding Corp (ICU) is a commercial-stage medical technology company that generates revenue through the sale of its proprietary Selective Cytopheretic Device (SCD), an extracorporeal therapy designed to modulate hyperinflammation in critically ill patients. The company’s business model centers on a high-margin, consumable-based transaction strategy where the SCD—branded as QUELIMMUNE for pediatric use—is sold as an add-on component to existing Continuous Renal Replacement Therapy (CRRT) systems. Primary business segments are bifurcated by patient population: the commercialized pediatric segment, which operates under a Humanitarian Device Exemption (HDE) for acute kidney injury (AKI) with sepsis, and the adult segment, currently advancing through the NEUTRALIZE-AKI pivotal trial. SeaStar Medical competes directly with CytoSorbents Corporation in the cytokine-reduction space and indirectly with diversified medtech giants like Baxter International and Fresenius Medical Care, positioning itself as a specialized, first-in-class immunomodulatory solution that integrates into, rather than replaces, established ICU dialysis infrastructure. Leadership is spearheaded by CEO Eric Schlorff, who brings over 20 years of financial and strategic experience from Dow Chemical, and Chief Medical Officer Col. (Ret.) Kevin Chung, MD, a former Chair of Medicine at the Uniformed Services University and a globally recognized expert in multi-organ support. The company was co-founded by Dr. H. David Humes, a Professor of Internal Medicine at the University of Michigan whose pioneering research in cell-directed therapy forms the scientific foundation of the SCD technology. The executive team is further supported by CFO Michael Messinger, a veteran of Lexicon Pharmaceuticals, and a board of directors chaired by Jennifer Baird. Notable board members include John Neuman, a former Dow executive, and Kenneth Van Heel, reflecting a strong pedigree in both clinical development and large-scale industrial operations.